Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study
Jazyk angličtina Země Spojené státy americké Médium electronic
Typ dokumentu dopisy, práce podpořená grantem
Grantová podpora
P30 CA015083
NCI NIH HHS - United States
PubMed
35581176
PubMed Central
PMC9114372
DOI
10.1038/s41408-022-00676-8
PII: 10.1038/s41408-022-00676-8
Knihovny.cz E-zdroje
- MeSH
- celogenomová asociační studie MeSH
- chronická lymfatická leukemie * genetika MeSH
- genetická predispozice k nemoci MeSH
- jednonukleotidový polymorfismus MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria
Centre for Individualised Infection Medicine Hannover Germany
CIBER Epidemiología y Salud Pública Madrid Spain
Department of Biology University of Pisa Pisa Italy
Department of Hematology University Hospital of Salamanca Salamanca Spain
Department of Quantitative Health Sciences Mayo Clinic Rochester MN 55905 USA
Division of Computational Genomics Mayo Clinic Rochester MN USA
Division of Hematology Mayo Clinic Rochester MN USA
Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany
Genomic Epidemiology Group German Cancer Research Center Heidelberg Germany
Hematology Department Hospital del Mar Barcelona Spain
Hematology Department Morales Meseguer University Hospital Murcia Spain
Hematology department Virgen de las Nieves University Hospital Granada Spain
Hopp Children's Cancer Center Heidelberg Germany
Hospital Campus de la Salud PTS Granada Granada Spain
Immunology Department Virgen de las Nieves University Hospital Granada Spain
Instituto de Investigación Biosanitaria IBs Granada Granada Spain
Josep Carreras Leukemia Research Institute Girona Spain
Medical University of Wrocław Wrocław Poland
Molecular Cytogenetics Laboratory Pathology Department Hospital del Mar Barcelona Spain
Zobrazit více v PubMed
Berndt SI, Camp NJ, Skibola CF, Vijai J, Wang Z, Gu J, et al. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat Commun. 2016;7:10933. doi: 10.1038/ncomms10933. PubMed DOI PMC
Lin WY, Fordham SE, Sunter N, Elstob C, Rahman T, Willmore E, et al. Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. Nat Commun. 2021;12:665. doi: 10.1038/s41467-020-20822-9. PubMed DOI PMC
Airoldi I, Raffaghello L, Cocco C, Guglielmino R, Roncella S, Fedeli F, et al. Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes. Clin Cancer Res. 2004;10:144–54. doi: 10.1158/1078-0432.ccr-1026-3. PubMed DOI
Bhalla S, Gordon LI. Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-cell chronic lymphocytic leukemia (CLL) Cancer Biol Ther. 2016;17:300–9. doi: 10.1080/15384047.2016.1139246. PubMed DOI PMC
Van Damme M, Crompot E, Meuleman N, Mineur P, Bron D, Lagneaux L, et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics. 2012;7:1403–12. doi: 10.4161/epi.22674. PubMed DOI PMC
Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, Reinhardt D, et al. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica. 2012;97:551–9. doi: 10.3324/haematol.2011.055236. PubMed DOI PMC
Yun X, Sun X, Hu X, Zhang H, Yin Z, Zhang X, et al. Prognostic and therapeutic value of apolipoprotein A and a new risk scoring system based on apolipoprotein a and adenosine deaminase in chronic lymphocytic leukemia. Front Oncol. 2021;11:698572. doi: 10.3389/fonc.2021.698572. PubMed DOI PMC
Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, et al. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2016;1:47–61. doi: 10.1182/bloodadvances.2016000984. PubMed DOI PMC
Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood. 2011;118:6141–52. doi: 10.1182/blood-2011-08-374728. PubMed DOI PMC
Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364–9. doi: 10.1136/jcp.51.5.364. PubMed DOI PMC
Sille FC, Thomas R, Smith MT, Conde L, Skibola CF. Post-GWAS functional characterization of susceptibility variants for chronic lymphocytic leukemia. PLoS ONE. 2012;7:e29632. doi: 10.1371/journal.pone.0029632. PubMed DOI PMC
De Matteis S, Molinari C, Abbati G, Rossi T, Napolitano R, Ghetti M, et al. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. J Transl Med. 2018;16:172. doi: 10.1186/s12967-018-1545-0. PubMed DOI PMC
Mpakou VE, Ioannidou HD, Konsta E, Vikentiou M, Spathis A, Kontsioti F, et al. Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia. Leuk Res. 2017;60:74–81. doi: 10.1016/j.leukres.2017.07.004. PubMed DOI
Jablonska E, Kiersnowska-Rogowska B, Aleksandrowicz-Bukin M, Rogowski F, Sawicka-Powierza J. TRAIL receptors in the serum of patients with B-cell chronic lymphocytic leukemia. Neoplasma. 2008;55:51–4. PubMed
Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, et al. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol. 2005;205:246–52. doi: 10.1002/jcp.20392. PubMed DOI
